Qing-Jin Yi-Qi granule for patients in the rehabilitation phase of COVID-19: a randomized controlled trial
- Conditions
- ovel Coronavirus Pneumonia (COVID-19) convalescence stage
- Registration Number
- ITMCTR2100004344
- Lead Sponsor
- Tianjin University of TCM
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Recruiting
- Sex
- All
- Target Recruitment
- Not specified
1) Patients who met the diagnostic criteria of covid-19 and discharged after treatment;
2) Aged 18-75 years;
3) Having one or more clinical manifestations of respiratory symptoms or fatigue;
4) Patient informed consent.
1) Patients who have undergone operations that affect lung function, such as lung transplantation, lung resection, lung volume reduction, etc;
2) Combined with chronic lung diseases that affect lung function, such as severe chronic obstructive pulmonary disease;
3) Patients complicated with diseases affecting cardiac function, such as pulmonary hypertension and heart failure;
4) Accompanied by severe underlying diseases, malignant tumor, severe malnutrition, etc;
5) Resting heart rate > 120/min;
6) Systolic blood pressure > 180mmhg or diastolic blood pressure > 100mmhg;
7) Severe obesity (BMI > 30kg/m2);
8) Allergic constitution, allergic to the drug components involved in the treatment program;
9) Patients who were judged by the investigator to be unable to comply with the study protocol;
10) Pregnant or lactating women.
Study & Design
- Study Type
- Interventional study
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method cough vas;Borg score;mMRC;
- Secondary Outcome Measures
Name Time Method TCM syndrom score;routine blood test;GAD-7 score;PHQ-9 score;